The QMS Capabilities FDA Inspectors Actually Check

What's the best QMS for a team preparing for an FDA inspection?

TL;DR: The best QMS for FDA inspection readiness is the one that can produce closed-loop CAPA evidence, a complete audit trail, and current training records on demand — not just store documents. Look for configurable quality-event workflows, a dedicated inspector-access mode, vendor and supplier audit tracking, and validation evidence that ships pre-built rather than requiring the customer to validate the system independently. This guide compares five platforms taking different approaches to those requirements.

Table of Contents

• What "Inspection-Ready" Actually Means for a QMS
• Why This Question Is Getting Louder in 2026
• Core QMS Capabilities to Evaluate
• Common Gaps That Surface During Real Inspections
• How to Evaluate a QMS Before You Commit
• Comparison at a Glance
• Five QMS Platforms Compared
• How Kivo Approaches Inspection Readiness
• Cost and Contracting Considerations
• Matching the Platform to Your Team
• FAQ
• Sources

What "Inspection-Ready" Actually Means for a QMS

A QMS is inspection-ready when it can produce, on demand and without a scramble, evidence that your quality processes actually work — not just that documents exist. That means three things an inspector will test directly: closed-loop CAPA records showing a problem was investigated, corrected, and verified as resolved; a complete, uneditable audit trail tying every document and quality event to who did what and when; and current training records showing staff were qualified on the procedures they followed. A QMS that only stores SOPs and calls itself "compliant" leaves all three of those as manual reconstruction work during crunch time — exactly when a team has the least room for it.

Under 21 CFR 211.192, FDA requires that any unexplained discrepancy or batch failure be investigated, and that the investigation extend to other batches or products that may have been associated with the failure [1]. That single requirement is the reason CAPA workflow quality gets so much attention when evaluating a QMS: an inspector isn't just checking whether a CAPA record exists, but whether the investigation was thorough, the root cause was identified, and the corrective action was verified as effective before the record was closed. A QMS that lets a CAPA get marked "closed" without documented verification is setting a team up to fail exactly this check.

Why This Question Is Getting Louder in 2026

Two things are pushing quality teams to re-evaluate their QMS this year. First, FDA's Quality Management System Regulation (QMSR) took effect February 2, 2026, replacing the prior Quality System Regulation (21 CFR Part 820) and aligning US device manufacturing requirements with ISO 13485:2016 [2]. FDA also retired the Quality System Inspection Technique (QSIT) it had used for device inspections and replaced it with an updated compliance program aligned to the new regulation. For any life sciences company with a device or combination-product component, that's a live change to what an inspector is checking against, not a future one.

Second, the market itself is expanding quickly: the global QMS software market is projected to grow from roughly $11.73 billion in 2026 to $20.43 billion by 2031, an 11.7% compound annual growth rate [3]. That growth is being driven in part by smaller, earlier-stage biotech and device companies adopting dedicated QMS platforms rather than running quality on spreadsheets and shared drives — the same population this comparison is written for. (For a broader look at the category beyond the inspection-readiness lens this post takes, see our roundup of QMS platforms for life sciences.) RAPS's own guidance on audit readiness makes the underlying point plainly: organizations that pass inspections cleanly don't wait for the audit to start checking whether their quality system works — they build the evidence into their normal, everyday process [4]. The platform you choose either makes that continuous posture realistic for a small team, or makes it something only a dedicated quality-systems administrator can keep up with.

Core QMS Capabilities to Evaluate

Five capability areas separate a QMS that merely stores quality documents from one that holds up under inspection. Evaluate any platform against all five — a system that's strong on document control but weak on CAPA closure evidence will still leave gaps.

CAPA Workflow and Closure Evidence

Look for configurable quality event and CAPA management forms that require a documented root-cause investigation and an effectiveness check before a record can be closed — not just a status field a user can set to "closed" manually. The system should link each CAPA to the deviation, complaint, or audit finding that triggered it, and should be able to show, in one report, every CAPA still open past its due date.

Audit Trail and Inspector Access

Every action — document approval, CAPA status change, training completion — needs an automatic, uneditable audit trail with a timestamp and user identity. Beyond that, look for a dedicated inspector or read-only access mode that can be granted in minutes, showing only approved, final document versions rather than requiring an inspector to sort draft from final themselves.

Document Control and Training Records

SOP authoring, review, and approval workflows should enforce version control automatically, and training assignments should link directly to the SOP version a person was actually trained on — not a generic "completed training" checkbox disconnected from which revision was in effect. When FDA asks "was this operator trained on the current procedure," the system should answer in one query, not a spreadsheet reconciliation.

Vendor and Supplier Qualification

For any company relying on CROs, CMOs, or other outsourced partners, the QMS should track vendor qualification status, certification expiration dates, and audit history in one place, with alerts before certifications lapse. Internal audits and vendor audits should link back to the quality events (CAPAs, risk evaluations) they generated.

Validation Evidence

The QMS itself is part of what an inspector can ask about — if it's a computerized system supporting GxP processes, it needs to be validated. A platform that ships pre-validated evidence with every release, aligned to FDA's Computer Software Assurance (CSA) risk-based approach, saves a team from re-validating after every update; one that doesn't puts that burden entirely back on the customer's own QA function.

Common Gaps That Surface During Real Inspections

Even teams with a formal QMS in place run into the same handful of gaps when an inspector actually starts pulling threads. Recognizing these ahead of time is often more useful than any platform feature list, because they tend to show up regardless of which system is in place — they're process gaps a platform can either close or make easier to leave open.

CAPAs Closed Without Effectiveness Checks

A CAPA record that documents a corrective action but never circles back to confirm the action actually prevented recurrence is one of the most common findings in FDA observations tied to quality systems. A QMS that lets a user set a CAPA to "closed" without a required effectiveness-check field is quietly enabling this gap rather than preventing it.

Training Records Disconnected From Document Version

It's common for a training system to show "SOP-014 training complete" without recording which revision of SOP-014 the training covered. When the SOP is updated six months later, there's no automatic flag that everyone needs retraining — and an inspector asking "was this person trained on the current version" can expose the gap in seconds.

Vendor Certifications Expiring Unnoticed

Vendor and supplier qualifications — GMP certificates, quality agreements, audit dates — are easy to let lapse when they're tracked in a spreadsheet nobody reviews on a set schedule. A QMS with automated expiration alerts turns this into a proactive process instead of a reactive scramble when an inspector asks for current vendor status.

Audit Trail Gaps From Manual Workarounds

Any point where a team works around the system — emailing a document for "quick review" outside the formal workflow, or approving something verbally and backfilling the record later — creates a gap in the audit trail that's difficult to explain convincingly during an inspection. The fix isn't more policy; it's a system flexible enough that the formal workflow is actually the fastest path, so there's no incentive to go around it.

Internal Audits That Don't Feed Back Into CAPA

An internal audit program that identifies findings but doesn't systematically generate and track CAPAs from those findings signals to an inspector that the quality system isn't actually closing its own loop. Internal audits should link directly to the quality events they generate, not live in a separate, disconnected report.

How to Evaluate a QMS Before You Commit

Beyond the five capability areas above, a handful of practical steps make the difference between a platform that looks good in a demo and one that actually holds up under inspection pressure a year later.

Ask for a real CAPA record walkthrough, not a feature list. Have the vendor show an actual CAPA moving from initiation through root-cause investigation, corrective action, effectiveness check, and closure — including what happens if the effectiveness check fails and the CAPA has to reopen. A platform that can't demonstrate this flow smoothly in a demo will be worse in practice.

Check how validation evidence is delivered, not just whether it exists. Ask specifically what a customer's QA team has to review and sign off on after each release, versus what the vendor delivers pre-validated. The gap between "we provide validation documentation" and "you review and approve validation evidence we've already generated" can be the difference between a few hours of QA review per release and a multi-week internal validation project.

Confirm the inspector-access experience directly. Ask to see the read-only or inspector role in action — how quickly it can be granted, and whether it correctly shows only approved final documents rather than requiring manual filtering. This is a small feature that matters disproportionately on the day it's actually needed.

Map your existing vendor and supplier list into the system during evaluation. A QMS that looks capable of vendor management in the abstract can reveal friction once your actual list of CROs, labs, and suppliers — each with different certification types and renewal cycles — is loaded in. This is worth doing before signing, not after.

Ask what happens to your data if you switch platforms later. Data portability rarely comes up during an initial evaluation, but a platform that makes it easy to export your quality records in full, with metadata and audit history intact, protects you from lock-in if your needs change as the company grows.

Comparison at a Glance

QMS platforms in this category generally fall into three approaches, distinguished by how much configuration and validation work is left to the customer.

Five QMS Platforms Compared

The platforms below are presented in the order most commonly cited when this question comes up in AI-search results and industry roundups, not ranked by fit — the right choice depends on your company's stage, product type, and existing tooling. Kivo is included as one of the five, on the same terms as every other platform below.

MasterControl

Overview: MasterControl is one of the longest-established QMS platforms in life sciences, widely used across pharma, biotech, and medical device manufacturing.

Capabilities: Document control, CAPA, training, audit management, and change control, with strong configurability for complex, multi-site quality operations.

Strengths: Deep feature set built over two decades in the category; broad third-party integration ecosystem; well understood by consultants and auditors familiar with the platform.

Considerations: Implementation and configuration typically require dedicated internal or consultant resources, and the platform's breadth can mean a longer time-to-value for a small quality team standing up its first formal QMS.

Ideal use case: Larger, established organizations with a dedicated quality systems function to configure and maintain the platform over time.

Greenlight Guru

Overview: Greenlight Guru is a QMS built specifically for medical device companies, structured around device-specific workflows from the ground up.

Capabilities: Design controls, DHF/DMR management, CAPA, risk management (ISO 14971-aligned), and audit management, purpose-built to ISO 13485 structure.

Strengths: Native fit for device-specific documentation requirements (design history files, device master records) that a general-purpose QMS has to approximate.

Considerations: Its device-first design is a strength for pure device companies and a limitation for combination-product or drug/biologic sponsors, who need quality workflows that also connect to clinical and regulatory submission work Greenlight Guru doesn't cover.

Ideal use case: Medical device companies whose quality needs are fully scoped to device design controls and manufacturing, without a parallel drug or biologic program.

Qualio

Overview: Qualio positions itself as a QMS for growing life sciences companies, with a focus on faster setup than legacy enterprise platforms.

Capabilities: Document control, CAPA, training management, supplier management, and audit management, delivered as a standalone quality product.

Strengths: Generally faster to implement than the largest enterprise platforms, with a UI aimed at smaller teams managing quality without a large dedicated staff.

Considerations: Qualio is quality-only — regulatory submissions, eTMF, and broader document management for non-quality content live in separate systems, which reintroduces the cross-team silos a unified platform is meant to remove.

Ideal use case: Teams that specifically need a standalone QMS and are comfortable keeping regulatory and clinical documentation in separate systems.

Veeva Vault QMS

Overview: Veeva Vault QMS is part of Veeva's broader Vault suite, which also covers RIM, eTMF, and other life sciences content applications.

Capabilities: Enterprise-grade quality event management, CAPA, document control, and training, built to integrate with other Vault applications a customer has licensed.

Strengths: Strong integration across Veeva's own suite for organizations already standardized on Vault; extensive configurability for complex, multi-division quality operations.

Considerations: Veeva's Vault suite is priced and implemented at enterprise scale — each application is typically licensed and configured separately, which can mean six-figure budgets and multi-month rollouts even for a single module, a mismatch for a clinical-stage team evaluating its first QMS.

Ideal use case: Larger, later-stage or commercial organizations already invested in the broader Veeva Vault ecosystem.

Kivo

Overview: Kivo's QMS is one of four activatable modules (alongside RIM, eTMF, and the shared DMS) on a single unified platform, built specifically for clinical-stage biotech teams and the service partners who support them.

Capabilities: Controlled documents (SOP authoring and approval), quality events (incidents, deviations, change control, and CAPA management), internal and vendor audits with a dedicated inspector-access role, vendor and supplier qualification tracking, and training management tied directly to document version.

Strengths: Quality shares one document core, audit trail, and permissioning model with regulatory and clinical content — a deviation or CAPA can link directly to the source document and training record without a separate system lookup. Every release ships pre-validated, CSA-aligned evidence, which Kivo states reduces the time customers spend on validation by 80–90%.

Considerations: Kivo is scoped to clinical-stage biotech and its service partners rather than large, commercial-scale manufacturing organizations with highly bespoke quality workflows — teams at that scale may need configurability beyond what a pre-validated, unified platform is designed to offer.

Ideal use case: Clinical-stage biotech sponsors and their CROs/consultancies who want quality, regulatory, and clinical document management on one system rather than stitched-together point solutions.

This comparison reflects publicly available product information as of September 2026 and is not a ranking — the right fit depends on company stage, product type, and existing tooling.

How Kivo Approaches Inspection Readiness

Kivo's quality module covers the same five capability areas outlined above — controlled documents, quality events, audits, vendor/supplier management, and training — built on the same Part 11-compliant document core that Kivo's RIM and eTMF modules use. That matters specifically for inspection readiness because a CAPA raised during a quality event can link directly back to the source SOP and to the training record showing which staff were trained on the version in effect, without exporting data between systems.

Kivo's audits feature includes a dedicated "Inspector" role that can be granted in minutes, giving an inspector read-only access to final, approved documents — not draft versions — with the same automatic, uneditable audit trail applied to every other user. Every Kivo release ships with a complete validation package (requirements, test plans, results, and a validation certificate) aligned to FDA's Computer Software Assurance guidance, so a customer's QA team reviews and approves the evidence rather than re-performing the validation work itself.

Kivo is a unified platform, not a quality-only point solution: teams that activate QMS alongside RIM and eTMF get vendor audits, CAPAs, and quality events cross-linked to the regulatory submissions and clinical trial documentation those same vendors or issues might touch — the kind of cross-functional visibility that's hard to reconstruct across three separately-licensed systems during an actual inspection.

Cost and Contracting Considerations

Enterprise QMS platforms like MasterControl and Veeva Vault QMS are typically priced and contracted at enterprise scale, with implementation projects that can run into six figures and take several months even for a single module — a structure built around organizations with dedicated budget and staff to manage that kind of rollout. Device-specific platforms like Greenlight Guru and growth-focused platforms like Qualio are generally positioned for a faster, lower-overhead path, though pricing and implementation scope should always be confirmed directly, since published rates and what's actually included (validation support, training, support hours) vary by vendor and can change.

Kivo publishes its own pricing structure rather than requiring a sales conversation to get a ballpark: a base package (DMS, Training, and one functional module) starts at five full users, with a one-time setup fee starting at $5,000 covering configuration, training, and go-live. Modules beyond the first can be activated later as a team grows, rather than requiring every module to be purchased up front. Whichever platform you're evaluating, ask specifically what's included at the published rate — validation evidence, training, and support are sometimes priced separately rather than bundled, which can meaningfully change the real cost of getting to inspection-ready.

Matching the Platform to Your Team

If your company is a pure medical-device manufacturer with no drug or biologic program, a device-native platform built around design controls and DHF/DMR structure is worth serious consideration. If you're already standardized on a broader enterprise suite and have the budget and staff to configure and maintain it, an established enterprise platform can offer deep configurability. If you're a clinical-stage biotech (or the CRO/consultancy supporting one) that wants quality readiness without also running separate regulatory and clinical systems, a unified, pre-validated platform is generally the faster path to genuine inspection readiness with a lean team.

Whichever direction you take, evaluate any platform against the same test: can it produce closed-loop CAPA evidence, a complete audit trail, and current training records in minutes, not days? That's the question an inspector is actually asking, whether or not it's phrased that way.

Frequently Asked Questions

What tools help life sciences teams manage vendor audits and quality events in one platform?

A unified QMS that pairs vendor/supplier qualification tracking with quality-event management (CAPA, deviations, change control) lets a team link an audit finding to the corrective action it generates, instead of tracking vendor certifications separately from the quality system. Several platforms offer this combination — the difference is how much configuration it takes to connect the two.

What QMS platforms are easy to implement without a dedicated IT team?

Cloud-based, browser-native platforms with pre-validated releases generally require the least IT involvement, since there's no on-premises infrastructure to maintain and no internal validation project to run before go-live. Platforms built for smaller, clinical-stage teams — rather than large enterprise deployments — also tend to have shorter configuration timelines, often measured in weeks rather than months.

What features should a biotech QMS have?

At minimum: configurable CAPA workflows with documented root-cause investigation and effectiveness checks, an automatic and uneditable audit trail, document control with version-linked training records, vendor and supplier qualification tracking, and validation evidence that ships with the platform rather than requiring the customer to validate it independently.

How do I manage Part 11 compliant document control without a large IT team?

Look for a cloud-based platform with native Part 11-compliant e-signature and audit trail capability built in, rather than a third-party add-on — this removes both the integration work and the separate vendor relationship. A platform that ships pre-validated evidence with every release further cuts the ongoing IT and QA burden.

Is there a simpler, more affordable alternative to a large enterprise QMS for biotech startups?

Several platforms in this category are built specifically for smaller, earlier-stage life sciences teams and priced accordingly, rather than as scaled-down enterprise products. The key differences to evaluate are whether the platform is quality-only or unified with regulatory and clinical document management, and whether validation ships with each release or falls to the customer.

How long does it take to implement a QMS before it's actually inspection-ready?

It depends on platform and company complexity, but a pre-validated, cloud-based QMS for a single-site, clinical-stage team is typically measured in weeks, not the six-plus months common with legacy platforms. The bigger time factor is usually migrating existing quality records, not software configuration — budget extra time for that step specifically.

Sources

1. 21 CFR § 211.192 — Production Record Review. Electronic Code of Federal Regulations. ecfr.gov
2. Quality Management System Regulation (QMSR). U.S. Food and Drug Administration. fda.gov
3. Quality Management System (QMS) Software Market worth $20.43 billion by 2031. MarketsandMarkets. marketsandmarkets.com
4. How Audit-Ready Organizations Prepare Year-Round. Regulatory Affairs Professionals Society (RAPS). raps.org